(Finance) – AbbViean American multinational active in the biopharmaceutical sector, closed the first quarter of 2024 with Net revenues of $12.31 billion, up 0.7% on a reported basis, or 1.6% on an operating basis. L’attributable net profit to AbbVie shareholders was 1,369 million dollars (vs. 239 million dollars a year ago). EPS was $0.77, whileAdjusted EPS was $2.31 (beating estimates of $2.23 per share).
The company has increased adjusted EPS guidance for full-year 2024 from $10.97-11.17 to $11.13-11.33, which includes an unfavorable impact of $0.08 per share related to acquired intellectual property rights and protections and key expenses incurred during the first quarter of 2024 .
“We continue to demonstrate exceptional operational execution and have delivered another quarter of strong results,” he said Richard A. Gonzalez, CEO by AbbVie – I couldn’t be more proud of the organization we’ve built over the last 11 years.”
“I would like to thank Rick for his exceptional leadership since AbbVie’s inception and am deeply honored to serve as the company’s next CEO,” he said. Robert A. Michael, president and chief operating officer – First quarter results were well above our expectations, driven by the excellent performance of our ex-Humira growth platform. Based on our strong results and significant momentum, we are improving our full-year outlook.”